A vaccine for all mankind: Sputnik V's efficacy in fighting COVID-19 is validated by internationally peer reviewed data published in The Lancet In an interim analysis of a Phase III clinical trial, Sputnik V showed Efficacy of Sputnik V against COVID-19 was reported at 91.6%. - Analysis included data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases. - Efficacy in the elderly group of 2,144 volunteers over 60 years old was 91.8% and did not differ statistically from the 18-60 group. Sputnik V provides full protection against severe cases of COVID-19.